Planned & Ongoing Studies

SanoStem has partnered with Dr. Anant Bagul of University & Chaittnya Hospitals, Pune, India to conduct 1 clinical trial using MSC for Type 2 Diabetes Mellitus (T2DM): 114 subjects will be enrolled & randomized 1:1

Main Inclusion Criteria:

Males & females 18 to 75 years of age

Poor glycemic control with A1C of 8.0% to 11.0% (both inclusive)

Any combination of Injectable & oral anti-diabetic meds & or insulin


In August 2014, SanoStem received approval from the Health Authority of Fiji to begin a clinical trial for ischemic stroke using both NSC & MSC.


Stemedica has 6 FDA approved Phase I/II clinical trials in USA:

  • Ischemic Stroke – Phase IIa completed. Awaiting publication.
  • Congestive Heart Failure (CHF) Phase IIa completed & published. Will advance to Phase III
  • Acute Myocardial Infarction (AMI)
  • Cutaneous PhotoAging
  • Alzheimer’s Disease (AD)
  • Traumatic Brain Injury (TBI)


Some other potential indications for stem cell research:

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Diabetic Retinopathy
  • Macular Degeneration
  • Metabolic Syndrome
  • Multiple Sclerosis
  • Peripheral Vascular Disease
  • Spinal Cord Injury
  • Spinal Muscular Atrophy (SMA)
  • Erectile Dysfunction
  • Hair Loss
  • Osteoarthritis Knee (OA Knee): Protocol developed